Pharmacy benefit management

From Wikipedia, the free encyclopedia
  (Redirected from Pharmacy Benefit Management)
Jump to: navigation, search

In the United States, a pharmacy benefit manager (PBM) is most often a third party administrator (TPA) of prescription drug programs but sometimes can be a service inside of an integrated healthcare system (e.g.: Kaiser or VA). They are primarily responsible for processing and paying prescription drug claims.[1] They also are responsible for developing and maintaining the formulary, contracting with pharmacies, and negotiating discounts and rebates with drug manufacturers. Fortune 500 employers and public purchasers (Part D, the Federal Employees Health Benefits Program) provide prescription drug benefits to the vast majority of American workers and retirees. There are fewer than 100 major companies in this category in the US.[2][citation needed]

According to the American Pharmacists Association (APhA), "Historically, a pharmacy benefit manager (PBM) is a third-party administrator of prescription drug programs. PBMs are primarily responsible for developing and maintaining the formulary, contracting with pharmacies, negotiating discounts and rebates with drug manufacturers, and processing and paying prescription drug claims. For the most part, they work with self-insured companies and government programs striving to maintain or reduce the pharmacy expenditures of the plan while concurrently trying to improve health care outcomes."[1]

Scope of PBMs[edit]

PBMs aggregate the buying clout of millions of enrollees through their client health plans, enabling plan sponsors and individuals to obtain lower prices for their prescription drugs through price discounts from retail pharmacies, rebates from pharmaceutical manufacturers, and the efficiencies of mail-service pharmacies.

History of PBMs[edit]

PBMs originated during the "1970s to serve as fiscal intermediaries by adjudicating prescription drug claims by paper and then, in the 1980s, electronically."[3]:34 Diversified Pharmaceutical Services (DPS) was one of the earliest examples of a pharmacy benefit manager that entered the market from within a leading national Health maintenance organization (HMO) United HealthCare (now United HealthGroup).[4]:304[5] Diversified pioneered many cost containment strategies that are now core PBM services and became a recognized leader in clinical programs.[citation needed] After its acquisition by SmithKline Beecham in 1994, Diversified played a pivotal role in that company's Healthcare Service division. By 1999 UnitedHealth Group accounted for 44% of DPS's total membership.[5] Express Scripts acquired Diversified April 1, 1999 and consolidated its position as a leading PBM for managed care organizations.[5]

By 2007 the function of PBMs had changed "from simply processing prescription transactions to managing the pharmacy benefit for health plans,"[3]:34 negotiating "drug discounts with pharmaceutical manufacturers,"[3]:34 providing "drug utilization reviews and disease management."[3]:34 PBMs also created a formulary that encouraged or even required "health plan participants to use preferred formulary products to treat their conditions."[3]:34

Major PBMs[edit]

In 2015,the three largest public PBMs were Express Scripts, CVS Health (formerly CVS Caremark) and United Health/OptumRx/Catamaran.[6][7][8] In 2015, the largest private PBM was Prime Therapeutics, a PBM owned by and operated for a collection of state Blue Cross Blue Shield plans.

Express Scripts[edit]

Express Scripts Holding Company is the largest pharmacy benefit management (PBM) organization in the United States,[9] with 2013 revenues of $104.62 billion.[10] In 2012 Express Scripts' $29.1 billion acquisition of rival Medco Health Solutions (once the nation's largest PBM) created "a powerhouse in managing prescription drug benefits."[11]

In October 2015 Express Scripts began reviewing pharmacy programs run by AbbVie Inc and Teva Pharmaceuticals Industries Ltd regarding the potential use of tactics that "can allow drugmakers to work around reimbursement restrictions" from Express Scripts and other insurers. Insurers like Express Scripts direct "patients to cheaper generic versions of widely-used medicines to save costs." These reviews resulted from investigations into "questionable practices" at Valeant Pharmaceuticals International Inc's partner pharmacy, Philidor Rx Services.[9]

CVS Health[edit]

In 1994, CVS launched PharmaCare, a pharmacy benefit management (PBM) company providing a wide range of services to employers, managed care organizations, insurance companies, unions and government agencies.[12] By 2002 CVS' specialty pharmacy ProCare, the "largest integrated retail/mail provider of specialty pharmacy services" in the United States,[13]:10 was consolidated with their pharmacy benefit management company, PharmaCare.[13][14]:4 Caremark Rx Caremark which was originally founded as a unit of Baxter International and was spun off from Baxter in 1992 as a publicly traded company. In March 2007, Caremark merged with CVS Corporation to create CVS Caremark, later re-branded as CVS Health.[15]

In 2011 Caremark Rx was the nation's second-largest PBM. Caremark Rx was subject to a class action lawsuit in Tennessee. The suit alleged that Caremark kept discounts from drug manufacturers instead of sharing them with member benefit plans, secretly negotiated rebates for drugs and kept the money, and provided plan members with more expensive drugs when less expensive alternatives were available. CVS Caremark paid $20 million to three states over fraud allegations.[16]

UnitedHealth Group[edit]

OptumRx, a leading PBM is one of the Optum businesses of UnitedHealth Group Inc.[17] — the largest single health carrier in the United States.[18] UnitedHealth Group — then-UnitedHealthCare Corporation — was created in 1977. UnitedHealthCare Corporation was renamed in 1998). UnitedHealthCare Corporation acquired Charter Med Incorporated in 1977. Charter Med Incorporated was founded in 1974. UnitedHealthCare Corporation had its origins in the development of the HMO.[19] In March 2015 UnitedHealth Group acquired Catamaran Corporation for about $12.8 billion to extend its PBM business.[20][21]

PBMs operate in a marketplace where competition has been described as “vigorous” by the Federal Trade Commission (FTC).[22] Currently, in the United States, a majority of the large managed prescription drug benefit expenditures are conducted by about 60 PBMs.[23] While many PBMs are independently owned and operated, some are subsidiaries of managed care plans, major chain drug stores, or other retail outlets. PBMs compete to win business by offering their clients administrative and clinically based services which manage drug spending by enhancing price competition and increasing the cost-effectiveness of medications.[citation needed]

PBM strategies and tools[edit]

All PBMs offer a core set of services to manage the cost and utilization of prescription drugs and improve the value of plan sponsors' drug benefits. Some offer additional tools, such as disease management, that can target specific clinical problems for intervention. It is up to the client of the PBM, however, to determine the extent to which these tools will be employed.[citation needed]

Such tools include:[citation needed]

  • Pharmacy networks — PBMs build networks of retail pharmacies, known as preferred pharmacy network, to provide consumers convenient access to prescriptions at discounted rates. PBMs monitor prescription safety across all the network pharmacies, alerting pharmacists to potential drug interactions even if a consumer uses multiple pharmacies.
  • Mail service pharmacies — PBMs provide mail-service pharmacies that supply home-delivered prescriptions without the face-to-face consultation provided by a pharmacist. A 2013 CMS study found negotiated prices at mail order pharmacy to be up to 83% higher than the negotiated prices at community pharmacies.[24]

In 1995 the US FDA found the temperature in a mail box in the sun could reach 136°F (58°C) while the ambient air temperature was 101°F (38°C).[25] One of the arguments for specialty pharmacies offered by PBMs included concerns about temperature-sensitive pharmaceuticals through regular mail and parcel post. PBMs use insulated shipping container and ship drugs by express mail and couriers to reduce transit time. This may involve delivery to the door, rather than a mail box. This reduces risks to drug safety and efficacy but increases cost.

  • Formularies — PBMs use panels of independent physicians, pharmacists, and other clinical experts to develop lists of drugs approved for reimbursement in order to encourage clinically appropriate and cost-effective prescribing; PBM clients always have the final say over what drugs are included on the formulary that they offer to their employees or members.
  • Plan design — PBMs advise their clients on ways to structure drug benefits to encourage the use of lower cost drug alternatives — such as generics — when appropriate. This is done by setting plans up with different copay tiers, in this case the client will apply a lower copay for generic drugs than it would for brand drugs. The PBMs’ role is advisory only; the client retains all responsibility for establishing the plan design.
  • Electronic prescribing (E-prescribing) — PBMs have devised e-prescribing technology, which provides physicians with clinical and cost information on prescription options that allows them to better counsel consumers on which medications—including various lower cost options—will be the safest and most affordable choices. PBMs led the effort to increase the use of e-prescribing in Medicare.[26] Financial incentives for physicians to adopt health information technology (HIT) included in the recent economic stimulus bill will increase the number of prescribers using e-prescribing to more than 75 percent over the next five years—nearly double the rate of use anticipated after passage of last year’s e-prescribing legislation.[27] Research has found that e-prescribing will help prevent 3.5 million harmful medication errors and save the federal government $22 billion in drug and medical costs over the next 10 years, offsetting the projected $19 billion in federal outlays to modernize the nation’s HIT infrastructure under the American Recovery and Reinvestment Act (known as ARRA).[27]
  • Manufacturer discounts — PBMs pool purchasing power to negotiate substantial discounts from pharmaceutical manufacturers in order to lower benefit costs for clients and consumers.
  • Clinical management — PBMs use a variety of tools such as drug utilization review and disease management to encourage the best clinical outcomes for patients.
  • Pharmacy discount cards — PBMs are able to offer the uninsured their prenegotiated drug prices through the use of a pharmacy discount card. These discount cards can save users without insurance from between 10% and 75% on prescription medication, however many independent pharmacies offer prescriptions at or below the recommended price by a discount program.

Litigation over PBM practices[edit]

In 2004, litigation added to the uncertainty about PBM practices.[16][28]

State responses[edit]

In 2011 a new division of the Pharmacy Benefit Managers (PBM’s) was formed, with a mandate to license and regulate Pharmacy Benefit Managers (PBM’s) under the Mississippi Board of Pharmacy.[29]

State legislatures are using "transparency", "fiduciary", and "disclosure" provisions to regulate the business practices of PBMs.[28] The provisions require PBMs to disclose all rebate, discount, and revenue arrangements made with drug manufacturers, including all utilization information on covered individuals.

Fiduciary duty provisions have stirred the most controversy. They require PBMs to act in the best interest of health plans in a way that conflicts with PBMs' role as the intermediary, which is the foundation of the PBM industry. The Pharmaceutical Care Management Association, the national trade association representing PBMs, starkly opposes legislation of this kind. The PCMA believes public disclosure of confidential contract terms would damage competition and ultimately harm private and public sector consumers. The association also argues that transparency already exists for clients that structure contracts to best suit their needs, including imposing audit rights.

Maine, South Dakota, and the District of Columbia have laws requiring PBM transparency. PCMA filed suit against Maine and the District of Columbia for their financial disclosure laws.

In the Maine lawsuit, PCMA v. Rowe, PCMA alleged the law:

  • Destroys the competitive market and will result in higher drug costs for Maine consumers
  • Deprives PBMs of proprietary information and trade secrets
  • Violates the "taking and due process" clause of the U.S. and state constitutions
  • Allows for broad enforcement of violation under the Maine Unfair Trade Practices Act

PCMA won preliminary injunctions against the Maine law twice but was denied its motion for summary judgment. The judge agreed that financial disclosure was reasonable in relation to controlling the cost of prescription drugs. It was determined that the law was designed to create incentives within the market to curtail practices that are likely to unnecessarily increase costs without providing any corresponding benefit to those filling prescriptions. PCMA won an interim injunction against the D.C. law, with the judge ruling that it would be an "illegal taking" of private property.


PBMs have been strong proponents in the creation of a U.S. Food and Drug Administration (FDA) pathway to approve similar versions of expensive specialty drug that treat conditions like Alzheimer's, rheumatoid arthritis and multiple sclerosis.[30] So-called biosimilar legislation that does not grant brand name drug manufacturers monopoly pricing power[31] is strongly supported by PBMs, AARP, AFL-CIO, the Ford Motor Company, and dozens of other consumer, labor, and employer organizations concerned about runaway health care costs in both the private and public sector. A recent Federal Trade Commission (FTC) found that patents for biologic products already provide enough incentives for innovation and that additional periods of exclusivity would "not spur the creation of a new biologic drug or indication" and "imperils" the benefits of the approval process.[32]

See also[edit]


  1. ^ a b "Pharmacy Benefit Management" (PDF). American Pharmacists Association. 9 July 2009. Retrieved 4 November 2015. 
  2. ^ Schommer, J. C.; Brown, L. M.; Sogol, E. M. (15 February 2008). "Career Pathway Evaluation Program". American Journal of Pharmaceutical Education (Pharmacist Profile Survey) 72 (1): 2. PMC 2254227. Retrieved 4 November 2015. 
  3. ^ a b c d e Allison Dabbs Garrett; Robert Garis (2007). "Leveling the Playing Field in the Pharmacy Benefit Management Industry". Valparaiso University Law Review 42 (1): 33–80. Retrieved 31 October 2015. 
  4. ^ Peter Reid Kongstved (1995). Essentials of Managed Health Care. Barnes & Noble 1. 
  5. ^ a b c "Express Scripts to Acquire Diversified Pharmaceutical Services", PRNewswire (St. Louis), 9 February 1999, retrieved 31 October 2015 
  6. ^
  7. ^
  8. ^
  9. ^ a b Beasley, Deena (30 October 2015). "Exclusive: Beyond Valeant, U.S. payers scrutinize other drugmaker ties to pharmacies". Los Angeles: Reuters. Retrieved 1 November 2015. 
  10. ^ "Express Scripts Holding Company FORM 10-K". 2013. Retrieved 31 October 2015. 
  11. ^ Sierra, Michelle (22 July 2011). "Express Scripts takes $14 billion bridge loan". Reuters. Retrieved 31 October 2015. 
  12. ^ "CVS Caremark, Form 10-K, Annual Report, Filing Date Mar 29, 1995". Retrieved Mar 29, 2013. 
  13. ^ a b "CVS Annual Report" (PDF). CVS. 2001. Retrieved 17 October 2015. 
  14. ^ "Overview of the Specialty Drug Trend" (PDF). IMS Health. 2014. p. 11. Retrieved 5 October 2015. 
  15. ^ "CVS Caremark, Form 8-K, Current Report, Filing Date Mar 23, 2007" (PDF). Retrieved Mar 29, 2013. 
  16. ^ a b Pfeifer, Stuart (16 December 2011). "Money & Company". Los Angeles Times. Retrieved 17 January 2014. 
  17. ^ New Optum Product Helps Companies Better Manage Pharmacy Costs, Irvine, California, 18 October 2012, retrieved 31 October 2015 
  18. ^
  19. ^ "United HealthCare Corporation History". Retrieved 11 May 2015. 
  20. ^ Trefis Team (1 April 2015). "What The UnitedHealth-Catamaran Deal Means For Walgreens". Forbes. Retrieved 31 October 2015. 
  21. ^ "The Short Answer: Pharmacy-Benefit Managers". The Wall Street Journal. 30 March 2015. Retrieved 31 October 2015. 
  22. ^ US Federal Trade Commission & US Department of Justice Antitrust Division, “Improving Health Care: A Dose of Competition,” July 2004
  23. ^ Shepherd, Joanna (July 2013). "Is More Information Always Better? Mandatory Disclosure Regulations in the Prescription Drug Market". Cornell Law Review Online 99. Retrieved 31 October 2015. 
  24. ^
  25. ^ Black, J. C.; Layoff, T. "Summer of 1995 -Mailbox Temperature Excursions in St. Louis" (PDF). US FDA Division of Drug Analysis. Retrieved 31 October 2015. 
  26. ^ Perrone, M., “Electronic Prescribing Push Clicks with Congress,” The Associated Press, June 3, 2008; Mathews, A.W. and Radnofsky, L., “E-Prescribing Gets Support in Congress,” The Wall Street Journal, June 5, 2008.
  27. ^ a b Visante, “American Recovery and Reinvestment Act Will Save Billions and Reduce Medication Errors by Accelerating E-Prescribing,” prepared for the Pharmaceutical Care Management Association, March 2009,
  28. ^ a b Stan Finkelstein; Peter Temin (2008). Reasonable Rx: Solving the Drug Price Crisis. FT Press (Upper Saddle River, New Jersey, USA). p. 208. ISBN 978-0-132344494. 
  29. ^ "Newsletter" (PDF), Mississippi Board of Pharmacy (Madison, MS), April 2012, retrieved 31 October 2015 
  30. ^ Schouten, F. (29 July 2009), "Lobbyists battle over drug sales", USA Today, retrieved 31 October 2015 
  31. ^ "Our view on generic medications: Drugmakers seek excessive monopolies on ‘biologics’", USA Today, 12 August 2009, retrieved 31 October 2015 
  32. ^ "Follow-on Biologic Drug Competition", Federal Trade Commission, June 2009, retrieved 31 October 2015 

External links[edit]